The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years

[1]  Matthew J. Frigault,et al.  Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma , 2021, Leukemia.

[2]  N. Shah,et al.  Is There Still a Role for Allogeneic Transplantation in the Management of Lymphoma? , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  R. Bouabdallah,et al.  Haploidentical related donor compared to HLA-identical donor transplantation for chemosensitive Hodgkin lymphoma patients , 2020, BMC Cancer.

[4]  A. Szabo,et al.  Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT. , 2020, Blood advances.

[5]  R. Houot,et al.  Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation. , 2019, European journal of cancer.

[6]  S. Montoto,et al.  Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party , 2018, British journal of haematology.

[7]  K. Savage,et al.  Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Shipp,et al.  Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  R. Mahfouz,et al.  Nivolumab salvage therapy before or after allogeneic stem cell transplantation in Hodgkin lymphoma , 2017, Bone Marrow Transplantation.

[10]  R. Houot,et al.  Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. , 2017, Blood.

[11]  M. Shipp,et al.  Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  K. Savage,et al.  Nivolumab for classical Hodgkin lymphoma after autologous stem-cell transplantation and brentuximab vedotin failure: a prospective phase 2 multi-cohort study , 2016, The Lancet. Oncology.

[13]  Scott E. Smith,et al.  Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. , 2015, Blood.

[14]  M. Millenson,et al.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. , 2015, The New England journal of medicine.

[15]  L. Giordano,et al.  Unmanipulated haploidentical BMT following non-myeloablative conditioning and post-transplantation CY for advanced Hodgkin’s lymphoma , 2014, Bone Marrow Transplantation.

[16]  B. Savani,et al.  Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all! , 2014, Bone Marrow Transplantation.

[17]  J. Snowden,et al.  Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  S. Horning,et al.  Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant , 2013, Leukemia & lymphoma.

[19]  Scott E Smith,et al.  Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  D. Maloney,et al.  The role of autologous and allogeneic hematopoietic stem cell transplantation for Hodgkin lymphoma. , 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

[21]  A. Zelenetz,et al.  Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma , 2009, British journal of haematology.

[22]  N. Schmitz,et al.  Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin’s lymphoma: identification of prognostic factors predicting outcome , 2009, Haematologica.

[23]  A. Levis,et al.  Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. , 2008, Blood.

[24]  M. Maris,et al.  Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[25]  B. Cheson.  Overcoming mechanisms of RECISTance in lymphoma , 2007, Leukemia & lymphoma.

[26]  J. Garcia-conde,et al.  Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[27]  R. Gascoyne,et al.  High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. , 2005, Blood.

[28]  C. Craddock,et al.  Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation , 2005, The Lancet.

[29]  Dirk Hasenclever,et al.  Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial , 2002, The Lancet.

[30]  J. Armitage,et al.  Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  D. Winfield,et al.  Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial , 1993, The Lancet.

[32]  M. Crump,et al.  High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: importance of disease status at transplant. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  M. Bonab.  randomised trial , 2022 .

[34]  B. Coiffier,et al.  Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case-control study. Société Francaise de Greffe de Moelle. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  R. Gray.  A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .